Primary results of phase 3 AURIGA study indicated that dual maintenance therapy after transplant led to improved outcomes.

The phase 3 AURIGA study evaluated daratumumab (Darzalex) and lenalidomide vs lenalidomide maintenance in patients with newly diagnosed multiple myeloma who were in very good partial response, minimal ...

Panelists discuss how the IMROZ trial demonstrated improved outcomes with quadruplet therapy combining daratumumab, lenalidomide, melphalan, and prednisone in patients with transplant-ineligible newly ...

demonstrated that daratumumab, a monoclonal antibody that targets CD38, a protein found on the surface of myeloma cells, significantly reduces the risk of progression to active multiple myeloma ...

GSK continues to build the case for its multiple myeloma therapy Blenrep ... Johnson’s $10 billion-a-year anti-CD38 antibody Darzalex (daratumumab) with PomDex in the head-to-head DREAMM ...

It joins a number of other BCMA-directed therapies for multiple myeloma ... generated anti-CD38 blockbuster Darzalex (daratumumab). Talquetamab has also shown promise in myeloma in the phase ...

Previously we used to use Anti-CD38 ... myeloma also include the use of PCMA based therapy. BCMA is B-cell maturation antigen and it is a way for us to target the myeloma cell. So there are ...

The National Medical Products Administration or NMPA in China has approved Sarclisa, an anti-CD38 medicine, in combination with pomalidomide and dexamethasone or Pd to treat multiple myeloma or MM ...

an anti-CD38 medicine, in combination with pomalidomide and dexamethasone (Pd) for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior line of therapy ...